Top ▲
Target has curated data in GtoImmuPdb
Target id: 1303
Nomenclature: phosphodiesterase 4D
Abbreviated Name: PDE4D
Family: Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs)
Annotation status:
Awaiting annotation/under development. Please contact us if you can help with annotation.
» Email us
Gene and Protein Information ![]() |
||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | - | PDE4D | phosphodiesterase 4D | ||
Mouse | - | - | Pde4d | phosphodiesterase 4D | ||
Rat | - | - | Pde4d | phosphodiesterase 4D |
Database Links ![]() |
|
BRENDA | 3.1.4.17 |
CATH/Gene3D | 1.10.1300.10 |
DrugBank Target | Q08499 (Hs) |
Ensembl Gene | ENSG00000113448 (Hs), ENSMUSG00000074661 (Mm), ENSMUSG00000021699 (Mm) |
Entrez Gene | 5144 (Hs), 238871 (Mm), 24627 (Rn) |
Human Protein Atlas | ENSG00000113448 (Hs) |
KEGG Enzyme | 3.1.4.17 |
KEGG Gene | hsa:5144 (Hs), mmu:238871 (Mm), rno:24627 (Rn) |
OMIM | 600129 (Hs) |
SynPHARM |
13768 (in complex with Ro20-1724) 13769 (in complex with rolipram) 78414 (in complex with RS-25344) |
UniProtKB | Q08499 (Hs), Q01063 (Mm), P14270 (Rn) |
Wikipedia | PDE4D (Hs) |
Enzyme Reaction ![]() |
||||
|
Activator (Human) |
PKA-mediated phosphorylation [3] |
Rank order of affinity (Human) |
cyclic AMP >> cyclic GMP |
Download all structure-activity data for this target as a CSV file
Inhibitors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
The selective PDE4 inhibitor difamilast has been shown to inhibit PDE4D3 [6]. OPA-15406 is a Phase 2 clinical candidate being investigated as a treatment for atopic dermatitis [2]. |
Immuno Process Associations | |||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
1. Albrecht W, Unger A, Bauer SM, Laufer SA. (2017) Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases. J. Med. Chem., 60 (13): 5290-5305. [PMID:28613871]
2. Hanifin JM, Ellis CN, Frieden IJ, Fölster-Holst R, Stein Gold LF, Secci A, Smith AJ, Zhao C, Kornyeyeva E, Eichenfield LF. (2016) OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. J. Am. Acad. Dermatol., 75 (2): 297-305. [PMID:27189825]
3. Houslay MD, Adams DR. (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J., 370 (Pt 1): 1-18. [PMID:12444918]
4. Huang Z, Dias R, Jones T, Liu S, Styhler A, Claveau D, Otu F, Ng K, Laliberte F, Zhang L et al.. (2007) L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. Biochem. Pharmacol., 73 (12): 1971-81. [PMID:17428447]
5. Moslin R, Gardner D, Santella J, Zhang Y, Duncia JV, Liu C, Lin J, Tokarski JS, Strnad J, Pedicord D et al.. (2017) Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling. Medicinal Chemistry Communications, 8: 700-712. DOI: 10.1039/C6MD00560H
6. Okada M, Kato M, Sato N, Uno T, Kitagaki H, Haruta J, Hiyama H, Shibata T. (2007) Oxazole compound and pharmaceutical composition. Patent number: WO2007058338. Assignee: Otsuka Pharmaceutical Co., Ltd.. Priority date: 24/05/2007. Publication date: 15/11/2005.
7. Perry MJ, O'Connell J, Walker C, Crabbe T, Baldock D, Russell A, Lumb S, Huang Z, Howat D, Allen R et al.. (1998) CDP840: a novel inhibitor of PDE-4. Cell Biochem Biophys., 29: 113-32. [PMID:9631241]
8. Saldou N, Obernolte R, Huber A, Baecker PA, Wilhelm R, Alvarez R, Li B, Xia L, Callan O, Su C et al.. (1998) Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell. Signal., 10 (6): 427-40. [PMID:9720765]
9. Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, Chopra R. (2014) Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell. Signal., 26 (9): 2016-29. [PMID:24882690]
10. Tsai YF, Chu TC, Chang WY, Wu YC, Chang FR, Yang SC, Wu TY, Hsu YM, Chen CY, Chang SH et al.. (2017) 6-Hydroxy-5,7-dimethoxy-flavone suppresses the neutrophil respiratory burst via selective PDE4 inhibition to ameliorate acute lung injury. Free Radic. Biol. Med., 106: 379-392. [PMID:28263828]
11. Wang P, Myers JG, Wu P, Cheewatrakoolpong B, Egan RW, Billah MM. (1997) Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. Biochem. Biophys. Res. Commun., 234 (2): 320-4. [PMID:9177268]
Chen Yan.
Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs): phosphodiesterase 4D. Last modified on 20/06/2018. Accessed on 16/02/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303.